July 2019 FDA Recall Lisinopril And Hydrochlorothiazide by Lupin Pharmaceuticals Inc.
D-1581-2019 - Presence of Foreign Tablets/Capsules

This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on July 19, 2019 for the product Lisinopril And Hydrochlorothiazide. The FDA reported the reason for recall as presence of foreign tablets/capsules. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1581-2019

Reason for Recall
Presence of Foreign Tablets/Capsules: Product complaint received of one Fenofibrate tablet 145mg observed in 500 s count product bottle.
Initiated
07-19-2019
Reported
07-31-2019
Quantity
11,832 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Nationwide within the United States
Lisinopril and Hydrochlorothiazide Tablets USP, 20 mg/12.5 mg, 500-count bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775, INDIA, NDC 68180-519-02

Batch or Lot Expiration Information

Lot# :H801815, Exp. March 2021